P-131 Low-dose aspirin in combination with transarterial chemoembolization in treatment of unresectable hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the sixth and fourth common cancer in worldwide Egypt. Transarterial chemoembolization (TACE) standard treatment for unresectable HCC. Recent studies showed that TACE refractoriness impairs survival of HCC patients. Various strategies under investigation aim to improve outcome TACE, Aspirin demonstrated chemopreventive, antithrombotic anti-inflammatory properties Moreover, it has been reported aspirin may reverse apoptosis resistance cell lines. This study includes 60 patients diagnosed as indicted randomized two arms; control arm arm. All have vascular cellular compensated liver functions; platelets count ≥ 100,000, normal prothrombin time. We excluded with bleeding tendency, gastrointestinal ulcers, portal hypertension, allergy or contraindication aspirin. received 75 mg daily after meal 3 months; we assessed feasibility, toxicity aspirin, studied response disease progression. In this there was no significant difference between arms regarding baseline patients’ characteristics. Regarding compliance 70% were regular; 60% compliant versus 56.7% Most side effects are grade 1 effect. According modified RECIST criteria, better responses achieved arm; 10% had complete remission 6.7 %in 30% partial 23% arm, progression 40% however, didn’t reach statistical level (p=0.806). 20% developed vein thrombosis only 6.7% There an improvement free (PFS); median PFS not reached 11 months Control (P=0.035). The use adjuvant feasible be associated longer a tendency responses; larger sample size yield stronger results.